CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras

Summary

CSL and Alentis announced a global collaboration to develop and commercialize lixudebart for rare renal and hepatic diseases. Alentis will receive an upfront payment of $355 million and up to $1.2 billion in commercial milestones.